Assessment of the safety of long-acting β<inf>2</inf> -agonists in routine asthma care : The ASTRO-LAB protocol
| dc.contributor.author | Van Ganse, Eric | |
| dc.contributor.author | Texier, Nathalie | |
| dc.contributor.author | Dima, Alexandra L. | |
| dc.contributor.author | Laforest, Laurent | |
| dc.contributor.author | Ferrer, Montserrat | |
| dc.contributor.author | Hernandez, Gimena | |
| dc.contributor.author | Schuck, Stéphane | |
| dc.contributor.author | Herbage, Sandrine | |
| dc.contributor.author | Vial, Delphine | |
| dc.contributor.author | De Bruin, Marijn | |
| dc.contributor.institution | University of Aberdeen.University of Aberdeen | en |
| dc.contributor.institution | University of Aberdeen.Aberdeen Centre for Evaluation | en |
| dc.contributor.institution | University of Aberdeen.Aberdeen Health Psychology Group | en |
| dc.contributor.institution | University of Aberdeen.Institute of Applied Health Sciences | en |
| dc.date.accessioned | 2015-08-13T15:20:02Z | |
| dc.date.available | 2015-08-13T15:20:02Z | |
| dc.date.issued | 2015-06-18 | |
| dc.description | ASTRO-LAB is funded by the European Commission through the Seventh Framework Program (FP7-Grant Agreement n° 282 593) and gathers seven partners in a Consortium: Université Claude Bernard Lyon 1, University of Nottingham, Kappa Santé SAS, Cegedim Strategic Data Medical Research Limited, University of Amsterdam, Consortio Mar Parc de Salut de Barcelona and Lyon Ingénierie Projets. | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 5 | |
| dc.format.extent | 926160 | |
| dc.identifier | 54985532 | |
| dc.identifier | 1b578bb7-ba27-4121-b981-ed766e6a2a39 | |
| dc.identifier | 84935005937 | |
| dc.identifier.citation | Van Ganse, E, Texier, N, Dima, A L, Laforest, L, Ferrer, M, Hernandez, G, Schuck, S, Herbage, S, Vial, D & De Bruin, M 2015, 'Assessment of the safety of long-acting β <inf >2 </inf > -agonists in routine asthma care : The ASTRO-LAB protocol', npj Primary Care Respiratory Medicine, vol. 25, 15040. https://doi.org/10.1038/npjpcrm.2015.40 | en |
| dc.identifier.doi | 10.1038/npjpcrm.2015.40 | |
| dc.identifier.uri | http://hdl.handle.net/2164/4818 | |
| dc.identifier.url | http://www.scopus.com/inward/record.url?scp=84935005937&partnerID=8YFLogxK | en |
| dc.identifier.vol | 25 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | npj Primary Care Respiratory Medicine | en |
| dc.subject | SDG 3 - Good Health and Well-being | en |
| dc.subject | RA Public aspects of medicine | en |
| dc.subject | Public Health, Environmental and Occupational Health | en |
| dc.subject | Pulmonary and Respiratory Medicine | en |
| dc.subject.lcc | RA | en |
| dc.title | Assessment of the safety of long-acting β<inf>2</inf> -agonists in routine asthma care : The ASTRO-LAB protocol | en |
| dc.type | Journal article | en |
